• September 1 (THU)
  • September 2 (FRI)

Sep. 1 (Thu)

ASCO/KSMO Joint Symposium 1

Application of precision medicine in rare cancers: Approaching genetic landscape into rare cancers
Date & Time Sep. 1 (Thu), 09:00-10:15 Venue Room A
Presentation
Detail
  1. 1.Rare cancers in the multi-omic era
    Razelle Kurzrock (Medical College of Wisconsin, USA)
  2. 2.Basket trial for rare cancers and tissue agnostic approach
    Bhumsuk Keam (Seoul National University Hospital, Korea)
  3. 3.Challenges in adaptation of precision medicine to rare cancers
    Andrea Necchi (Vita-Salute San Raffaele University, Italy)

Scientific Symposium 1

Tissue-agnostic therapeutics
Date & Time Sep. 1 (Thu), 09:00-10:30 Venue Room B
Presentation
Detail
  1. 1.Immunotherapy as a tissue-agnostic drug: From discovery to future perspectives
    Dung T. Le (Johns Hopkins University School of Medicine, USA)
  2. 2.KRAS inhibitor as a tissue-agnostic drug?: From discovery to future perspectives
    David S. Hong (MD Anderson Cancer Center, USA)
  3. 3.Evolution of precision paradigm: Novel framework of clinical trial to support tumor-agonistic approach
    Vivek Subbiah (MD Anderson Cancer Center, USA)
  4. 4.Tumor-agnostic TRK inhibitor therapy for NTRK fusion-positive cancers
    Alexander Drilon (Memorial Sloan Kettering Cancer Center, USA)

Scientific Symposium 2

Proteomics & epigenomics – Updates, clinical application, clinical trial
Date & Time Sep. 1 (Thu), 09:00-10:30 Venue Room C
Presentation
Detail
  1. 1.Opportunity for proteomics-guided precision oncology
    Yu-Ju Chen (Academia Sinica, Taiwan)
  2. 2.Proteogenomics aspects in glioblastoma evolution by standard treatment
    Jong-Bae Park (National Cancer Center Graduate School of Cancer Science and Policy, Korea)
  3. 3.Proteogenomic analysis of human cancers
    Daehee Hwang (Seoul National University, Korea)
  4. 4.Genome-wide methylation analysis of cancers and application to early cancer diagnostics
    Duhee Bang (Yonsei University, Korea)

Plenary Lecture 1

Drug screening and oncology drug discovery
Date & Time Sep. 1 (Thu), 10:50-11:30 Venue Room A
Presentation
Detail
  1. 1.Drug screening and oncology drug discovery
    Todd Golub (Broad Institute and Dana-Farber Cancer Institute, USA)

Scientific Symposium 3

Up to date knowledge of GU cancer
Date & Time Sep. 1 (Thu), 12:40-14:10 Venue Room A
Presentation
Detail
  1. 1.New agents and advances into current prostate cancer treatment
    Himisha Beltran (Dana Farber Cancer Institute, Harvard Medical School, USA)
  2. 2.Treatment approaches with immunotherapy and targeted agents in RCC
    Woo Kyun Bae (Chonnam National University Hwasun Hospital, Korea)
  3. 3.Transforming treatment of advanced urothelial carcinoma
    Minsuk Kwon (Ajou University Hospital, Korea)
  4. 4.Gain special insights on targeting FGFR signaling in bladder cancer
    Ignacio Duran (Hospital Universitario Marques de Valdecilla-Idival Santander, Spain)

Scientific Symposium 4

Big data & AI: Cancer genome & diagnosis
Date & Time Sep. 1 (Thu), 12:40-14:10 Venue Room B
Presentation
Detail
  1. 1.Leverage big genomic data and advanced machine learning to discover new therapeutics for hepatocellular carcinoma
    Bin Chen (Michigan State University, USA)
  2. 2.Identification of patients with homologous recombination deficiency from sequencing data
    Peter Park (Harvard Medical School, USA)
  3. 3.Artificial intelligence-powered spatial analysis of tumor infiltrating lymphocytes correlated with distinct genomic profiles and clinical outcomes of immune checkpoint inhibitors
    Chan-Young Ock (Lunit Inc., Korea)
  4. 4.Computing cancer immunity for informing precision oncology
    Zlatko Trajanoski (Medical University of Innsbruck, Austria)

KSSO/KSMO Joint Symposium 2

Current issue & critical tip in MDT trial
Date & Time Sep. 1 (Thu), 14:30-15:30 Venue Room A
Presentation
Detail
  1. 1-2.현재 진행되고 있는 KCSG BR12-09 담도암 adjuvant trial
    Joon Oh Park (Samsung Medical Center, Korea)
    Joon Seong Park (Gangnam Severance Hospital, Korea)
  2. Discussion: Q&A
  3. 3-4.PRODIGY: A phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 Plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced Gastric Cancer
    Min Hee Ryu (Asan Medical Center, Korea)
    TBD (TBD)
  4. Discussion: Q&A

Multidisciplinary Oncology Team Education Session 1 Korean

Cancer associated complication management
Date & Time Sep. 1 (Thu), 14:30-15:30 Venue Room B
Presentation
Detail
  1. 1.Cardiovascular complication (except CAT/VTE)
    Yun-Gyoo Lee (Kangbuk Samsung Hospital, Korea)
  2. 2.Cancer associated thrombosis(CAT)/ Venous thromboembolism (VTE)
    Hee Jun Kim (Chung Ang University Hospital, Korea)
  3. 3.Chemotherapy-induced peripheral neuropathy (CIPN)
    Sung Hee Lim (Soonchunhyang University Bucheon Hospital, Korea)
  4. 4.Depression in cancer patients
    Hye Yoon Park (Seoul National University Hospital, Korea)

Oncology Multi-Disciplinary Symposium Korean

How to interpret BRCAs and beyond BRCAs gene mutations and how to manage cancer patients with those mutations
Date & Time Sep. 1 (Thu), 14:30-15:30 Venue Room C
Presentation
Detail
  1. 1.CASE I: Familial cancer patients: Consultation and management
    Young-gon Kim (Samsung Medical Center, Korea)
  2. Panel Discussion
  3. Young-gon Kim (Samsung Medical Center, Korea)
    Kyung-Hun Lee (Seoul National University Hospital, Korea)
    Sook-hee Hong (The Catholic University of Korea. Seoul St. Mary’s Hospital, Korea)
    Kyoung Eun Lee (Ewha Womans University Mokdong Hospital, Korea)
    Sungyoung Lee (Seoul National University Hospital)

  4. 2.CASE II: HRD testing in various cancers
    Kyung-Hun Lee (Seoul National University Hospital, Korea)
  5. Discussion: Q&A
  6. Young-gon Kim (Samsung Medical Center, Korea)
    Kyung-Hun Lee (Seoul National University Hospital, Korea)
    Sook-hee Hong (The Catholic University of Korea. Seoul St. Mary’s Hospital, Korea)
    Kyoung Eun Lee (Ewha Womans University Mokdong Hospital, Korea)
    Sungyoung Lee (Seoul National University Hospital)

Scientific Symposium 5

New horizons of clinical immuno-oncology in early-stage cancer
Date & Time Sep. 1 (Thu), 15:50-17:20 Venue Room A
Presentation
Detail
  1. 1.Promise and pitfalls of immune checkpoint inhibitors for early-stage cancers
    Dae Ho Lee (Asan Medical Center, Korea)
  2. 2.State-of-art of immunotherapy in early-stage NSCLC: Adjuvant vs. neoadjuvant?
    Sun Min Lim (Yonsei Cancer Center, Korea)
  3. 3.Beyond the immune-checkpoint inhibitors: Can intratumoral immunotherapy be another breakthrough?
    Stephane Champiat (Institute Gustave Roussy, France)
  4. 4.Current and future biomarkers of immuno-oncology in early-stage cancer
    Young Kwang Chae (Northwestern University, USA)

JSMO/KSMO Joint Symposium 3

Pharmacogenomics of targeted therapy and IO in Korea and Japan
Date & Time Sep. 1 (Thu), 15:50-17:20 Venue Room B
Presentation
Detail
  1. 1.Toxicity profile of targeted therapies and ADC in Asian patients
    Hidetoshi Hayashi (Kindai University, Japan)
  2. 2.Pharmacogenomics for immunotherapy and immune-related toxicities
    Sook Ryun Park (Asan Medical Center, Korea)
  3. 3.Management of metabolic adverse events of targeted therapies and ICI
    Eun Kyung Lee (National Cancer Center, Korea)
  4. 4.Pharmacogenomic-guided therapy in colorectal cancer
    Taroh Satoh (Osaka University Hospital, Japan)

Scientific Symposium 6

Clinical genomics
Date & Time Sep. 1 (Thu), 15:50-17:20 Venue Room C
Presentation
Detail
  1. 1.Improvement of patient care using cancer genomic profiling: SCRUM/CIRCULATE-Japan experience
    Atsushi Ohtsu (National Cancer Center Hospital East, Japan)
  2. 2.Creating accelerated access to genomics-guided precision medicine through innovative trials
    Emile E Voest (The Netherlands Cancer Institute, The Netherlands)
  3. 3.Sharing experiences in interpreting multi-institutional NGS reports for MTB discussions in the KOSMOS study
    Sejoon Lee (Seoul National University Bundang Hospital, Korea)
  4. 4.Current efforts and challenges in tumor-only sequencing
    Hongseok Yun (Seoul National University Hospital, Korea)

Plenary Lecture 2

AI based precision medicine
Date & Time Sep. 1 (Thu), 17:20-18:00 Venue Room A
Presentation
Detail
  1. 1.AI based precision medicine
    Fabrice Andre (The Institute Gustave-Roussy, France)

Sep. 2 (Fri)

Plenary Lecture 3

Mechanism-based biomarkers for PD-1 blockade in cancer therapy
Date & Time Sep. 2 (Fri), 09:00-09:40 Venue Room A
Presentation
Detail
  1. 1.Mechanism-based biomarkers for PD-1 blockade in cancer therapy
    Suzanne L. Topalian (Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, USA)

ASCO/KSMO Joint Symposium 4

Hereditary cancers: Diagnosis, management, and clinical trials
Date & Time Sep. 2 (Fri), 10:00-11:15 Venue Room A
Presentation
Detail
  1. 1.Lynch syndrome and MSI-H Cancers: Integration of ICI treatments
    Matthew Yurgelun (Dana-Farber Cancer Institute, USA)
  2. 2.Homologous Recombination Deficiency (HRD): "BRCAness" and clinical trials
    Seock-Ah Im (Seoul National University Hospital, Korea)
  3. 3.Heritable TP53-related cancer syndrome: Diagnostic and therapeutic implications of screening
    TBD (TBD)

KOSRO/KSMO Joint Symposium 5

Advance in radiotherapy and clinical application
Date & Time Sep. 2 (Fri), 10:00-11:30 Venue Room B
Presentation
Detail
  1. 1.Integration of SABR/SBRT into metastatic disease: From Oligometastases to Immune checkpoint
    Steven J. Chmura (University of Chicago, USA)
  2. 2.Image guided radiotherapy (IGRT), SNUH experience with MR guidance
    Eui Kyu Chie (Seoul National University Hospital, Korea)
  3. 3.Proton beam therapy
    Tae Hyun Kim (National Cancer Center, Korea)
  4. 4.Current status of carbon ion radiotherapy in Asia
    Tatsuya Ohno (Gumma University, Japan)

Scientific Symposium 7

Diffuse large B-cell lymphoma
Date & Time Sep. 2 (Fri), 10:00-11:30 Venue Room C
Presentation
Detail
  1. 1.The molecular substructure and classification of diffuse large B-cell lymphoma
    Margaret Shipp (Harvard Medical School, USA)
  2. 2.Double hit/triple hit lymphoma and high-grade B cell lymphoma, NOS
    Yoon Kyung Jeon (Seoul National University Hospital, Korea)
  3. 3.Bispecific T-cell engaging antibody therapy for DLBCL
    Tae Min Kim (Seoul National University Hospital, Korea)
  4. 4.CAR T-cell therapy for relapsed/refractory DLBCL
    Michael R. Bishop (University of Chicago Medicine, USA)

KCSG/KSMO Joint Symposium 6

New trends in clinical trials
Date & Time Sep. 2 (Fri), 12:40-14:10 Venue Room A
Presentation
Detail
  1. 1.Patient-centric clinical trials
    Aaron R. Hansen (Princess Alexandra Hospital, Metro South Health, Australia)
  2. 2.To reflect patient's voice in clinical trials: Perspectives on HRQOL and patient reported outcomes
    Juhee Cho (Samsung Medical Center, Korea)
  3. 3.Decentralized clinical trials: Basic concepts and experiences
    Aaron C. Tan (National Cancer Centre Singapore, Singapore)
  4. 4.To optimize decentralized clinical trials: Trends and challenges
    Heeyoung Kim (Medidata, Korea)

Special Symposium 1

Incorporating nuclear medicine theranostic approaches for cancer management
Date & Time Sep. 2 (Fri), 12:40-14:00 Venue Room B
Presentation
Detail
  1. 1.Peptide receptor radionuclide therapy and the treatment of neuroendocrine tumors
    David Tai Wai Meng (Singapore NCC, Singapore)
  2. 2.Clinical experience in development of PSMA-targeted imaging and therapy
    Joo Hyun O (The Catholic University of Korea St. Mary’s Hospital, Korea)
  3. 3.Current status of nuclear imaging in oncology; beyond FDG PET
    Yong-il Kim (Asan Medical Center, Korea)

Multidisciplinary Oncology Team Education Session 2Korean

ABCs of precision medicine (For beginners of precision medicine)
Date & Time Sep. 2 (Fri), 12:40-14:00 Venue Room C
Presentation
Detail
  1. 1.Basic concepts and elements of cancer genomics for the clinicians: For the very beginners of precision medicine
    Sehhoon Park (Samsung Medical Center, Korea)
  2. 2.How to apply cancer genome data to clinical practice and research
    Ji-Won Kim (Seoul National University Bundang Hospital, Korea)
  3. 3.Interpretation of immuno-oncology papers and planning for translational research
    Hyung-Don Kim (Asan Medical Center, Korea)
  4. 4.Things to know to interpret NGS report
    Yoon-La Choi (Samsung Medical Center, Korea)

Plenary Lecture 4

Harnessing DNA repair defects for cancer therapy
Date & Time Sep. 2 (Fri), 14:20-15:00 Venue Room A
Presentation
Detail
  1. 1.Harnessing DNA repair defects for cancer therapy
    Alan Ashworth (University of California San Francisco, USA)

KSP/KSMO Joint Symposium 7

Digital pathology & AI
Date & Time Sep. 2 (Fri), 15:00-16:30 Venue Room A
Presentation
Detail
  1. 1.Data-efficient and multimodal computational pathology
    Faisal Mahmood (Harvard Medical School, USA)
  2. 2.AI in urogenital pathology
    Sun Woo Kim (Deep Bio Inc., Korea)
  3. 3.Will artificial intelligence replace pathologist?
    Kee Taek Jang (Samsung Medical Center, Korea)
  4. 4.Moving beyond human capabilities in histopathology
    Geert Litjens (Radboud University Medical Center, The Netherlands)

Scientific Symposium 8

Esophageal squamous cell carcinoma
Date & Time Sep. 2 (Fri), 15:00-16:30 Venue Room B
Presentation
Detail
  1. 1.Principles and lessons for surgery in esophageal squamous cell carcinoma
    Chang Hyun Kang (Seoul National University Hospital, Korea)
  2. 2.Recent advances in radiation treatment for non-metastatic esophageal squamous cell carcinoma
    Sung Ho Moon (National Cancer Center, Korea)
  3. 3.Optimal adaptation of immune checkpoint inhibitors in locally advanced esophageal squamous cell carcinoma
    Jong-Mu Sun (Samsung Medical Center, Korea)
  4. 4.New treatment strategies for metastatic esophageal squamous cell carcinoma
    Ken Kato (National Cancer Center Hospital, Japan)

ESMO/KSMO Joint Symposium 8

Recent progress of precision medicine using genomic landscape in cooperation with agnostic approach
Date & Time Sep. 2 (Fri), 15:00-16:30 Venue Room C
Presentation
Detail
  1. 1.Tumor organoids: Opportunities and challenges to guide precision medicine
    Krisztian Homicsko (Lausanne University Hospital, Switzerland)
  2. 2.Current address to guide clinical decision-making in precision oncology in Europe
    David Planchard (Gustave Roussy, France)
  3. 3.Approach to risk-share for biomarker-driven treatment of rare subgroups of cancer patients
    Jean-Yves Blay (Léon Bérard Center, France)
  4. 4.Accelerating patient access to molecular profiling guided therapy based on genomic alterations in advanced solid tumors in Korea (KOSMOS project)
    Jee Hyun Kim (Seoul National University Bundang Hospital, Korea)

Scientific Symposium 9

Clinical development of radioligand therapy (RLT)
Date & Time Sep. 2 (Fri), 15:00-16:15 Venue Room D
Presentation
Detail
  1. 1.Overview of radioligand therapy: How radioligand therapy revolutionizes cancer treatment
    Hongyoon Choi (Seoul National University Hospital, Korea)
  2. 2.Advanced PSMA targeting therapy in prostate cancer
    Karim Fizazi (Gustave Roussy, France)
  3. 3.Radioligand therapies in development and future perspectives
    Germo Gericke (Advanced Accelerator Applications, Switzerland)

KSR/KSMO Joint Symposium 9

Machine learning tech in diagnostic radiology
Date & Time Sep. 2 (Fri), 16:40-17:40 Venue Room A
Presentation
Detail
  1. 1.Experience on radiogenomic study with breast MRI focusing on tumor heterogeneity
    Won Hwa Kim (Kyungpook National University Chilgok Hospital)
  2. 2.Brain Tumor
    Ho Sung Kim (Asan Medical Center, Korea)
  3. 3.Abdominal cancer
    Sungwon Kim (Severance Hospital, Korea)

Multidisciplinary Oncology Team Education Session 3 Korean

Familial cancer- Diagnosis, education, care
Date & Time Sep. 2 (Fri), 16:40-17:40 Venue Room B
Presentation
Detail
  1. 1.Hereditary breast cancer syndromes: Diagnosis and breast cancer risk management
    Sang Ah Han (Kyung Hee University Hospital at Gangdong, Korea)
  2. 2.Hereditary ovarian cancer: Prevention and therapeutic Implications
    Myong Cheol Lim (National Cancer Center, Korea)
  3. 3.Hereditary colorectal cancer syndromes & Li-Fraumeni syndrome: Diagnosis, cancer screening and preventive measures
    TBD (TBD)
  4. 4.Genetic testing and counselling of individuals at risk of hereditary cancer syndromes
    Sun-Young Kong (National Cancer Center, Korea)